Open Orphan PLC
LSE:ORPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Open Orphan PLC
EPS (Diluted)
Open Orphan PLC
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Open Orphan PLC
LSE:ORPH
|
EPS (Diluted)
£0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
EPS (Diluted)
£0
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
EPS (Diluted)
£0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genedrive PLC
LSE:GDR
|
EPS (Diluted)
£0
|
CAGR 3-Years
37%
|
CAGR 5-Years
49%
|
CAGR 10-Years
32%
|
|
|
Fusion Antibodies PLC
LSE:FAB
|
EPS (Diluted)
£0
|
CAGR 3-Years
48%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
EPS (Diluted)
£0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Open Orphan PLC
Glance View
Open Orphan Plc provides pharmaceutical development services. The firm is engaged in the testing of vaccines and antivirals using human clinical trials. The firm has a presence in the United Kingdom, Ireland, France and Netherlands. The Company, through its subsidiary hVIVO Limited, is also engaged in the data platform business. hVIVO Limited has built up databases of infectious disease progression data and the Company is populating its Open Orphan Health Data platform with hVIVO data. The firm also operates through its subsidiary Venn Life Sciences, which is an integrated drug development partner. Venn Life Sciences offers a combination of drug development consultancy, clinical trial design and execution to create, plan and execute drug development programs for its customers.
See Also
What is Open Orphan PLC's EPS (Diluted)?
EPS (Diluted)
0
GBP
Based on the financial report for Dec 31, 2022, Open Orphan PLC's EPS (Diluted) amounts to 0 GBP.
